Noelyn Hung

Dr. Noelyn Hung


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2015 in The Journal of Pathology: Clinical Research
Verified
Journal Article
Open access
PDF file
TSTania L. Slatter
Tania L. Slatter
HHHoward Hsia
Howard Hsia
ASAri Samaranayaka
Ari Samaranayaka
PSPeter Sykes
Peter Sykes
WCWilliam (Bill) Clow
William (Bill) Clow
NHNoelyn Hung
Noelyn Hung
Uterine smooth muscle tumours of uncertain malignant potential (STUMP) are diagnostically and clinically challenging. The alternative lengthening of telomeres (ALT) telomere maintenance mechanism is associated with poor survival in soft tissue leiomyosarcoma. Time to first recurrence and survival were known for 18 STUMP and 43 leiomyosarcomata (LMS). These were screened for ALT telomere maintenance by the presence of ALT‐associated PML bodies (APBs) and for changes associated with the ALT phenotype, namely aberrant p53 expression, isocitrate dehydrogenase 1 mutation (R132H substitution) expression, mutant ATRX (αthalassemia/mental retardation syndrome X‐linked) expression and mutant DAXX (death‐domain‐associated protein) expression by immunohistochemistry (IHC). Overexpression of p16INK4A was examined immunohistologically in a subset of cases. Many of the tumours associated with death or recurrence demonstrated APBs commensurate with ALT telomere maintenance. However, all uterine STUMP (4/4), and vaginal STUMP (2/2) patients, and almost all LMS patients (88.4%, 23/26, including 90% (9/10) of stage 1 LMS cases), who had died of disease or who had recurrent disease, displayed loss of ATRX or DAXX expression. Loss of ATRX or DAXX expression identified poor prognosis (95% CI 2.1 to 40.8, p < 0.003), in the LMS group. Thus, loss of ATRX or DAXX expression in uterine smooth muscle tumours identifies a clinically aggressive molecular subtype of early stage LMS and when histopathological features are problematic such as in STUMP. As ATRX and DAXX IHC is readily performed in diagnostic laboratories these are potentially useful for routine histopathological classification and management.

1 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
RERamona A. Eiholzer
Ramona A. Eiholzer
SMSunali Mehta
Sunali Mehta
MKMarina Kazantseva
Marina Kazantseva
CDCatherine Drummond
Catherine Drummond
CMCushla McKinney
Cushla McKinney
ABAntony Braithwaite
Antony Braithwaite
We investigated the influence of selected TP53 SNPs in exon 4 and intron 4 on cancer risk, clinicopathological features and expression of TP53 isoforms. The intron 4 SNPs were significantly over-represented in cohorts of mixed cancers compared to three ethnically matched controls, suggesting they confer increased cancer risk. Further analysis showed that heterozygosity at rs1042522(GC) and either of the two intronic SNPs rs9895829(TC) and rs2909430(AG) confer a 2.34–5.35-fold greater risk of developing cancer. These SNP combinations were found to be associated with shorter patient survival for glioblastoma and prostate cancer. Additionally, these SNPs were associated with tumor-promoting inflammation as evidenced by high levels of infiltrating immune cells and expression of the Δ133TP53 and TP53β transcripts. We propose that these SNP combinations allow increased expression of the Δ133p53 isoforms to promote the recruitment of immune cells that create an immunosuppressive environment leading to cancer progression.

1 January 2013 in Frontiers in Oncology
Verified
Journal Article
Open access
AAAnshul Awasthi
Anshul Awasthi
AWAdele Woolley
Adele Woolley
FLFabienne J. Lecomte
Fabienne J. Lecomte
NHNoelyn Hung
Noelyn Hung
BBBruce Baguley
Bruce Baguley
Joel TyndallJoel Tyndall
Joel Tyndall
GLI pathogenesis-related 1 (GLIPR1) was previously identified as an epigenetically regulated tumor suppressor in prostate cancer and, conversely, an oncoprotein in glioma. More recently, GLIPR1 was shown to be differentially expressed in other cancers including ovarian, acute myeloid leukemia, and Wilms’ tumor. Here we investigated GLIPR1 expression in metastatic melanoma cell lines and tissue. GLIPR1 was variably expressed in metastatic melanoma cells, and transcript levels correlated with degree of GLIPR1 promoter methylation in vitro. Elevated GLIPR1 levels were correlated with increased invasive potential, and siRNA-mediated knockdown of GLIPR1 expression resulted in reduced cell migration and proliferation in vitro. Immunohistochemical studies of melanoma tissue microarrays showed moderate to high staining for GLIPR1 in 50% of specimens analyzed. GLIPR1 staining was observed in normal skin in merocrine sweat glands, sebaceous glands, and hair follicles within the dermis.

12 August 2011 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
TSTania L Slatter
Tania L Slatter
XTXin Tan
Xin Tan
YYYi Ching Yuen
Yi Ching Yuen
SGSarah Gunningham
Sarah Gunningham
SMSally SiYan Ma
Sally SiYan Ma
NHNoelyn Hung
Noelyn Hung

6 March 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
NHNoelyn Hung
Noelyn Hung
YCYu-Jen Chen
Yu-Jen Chen
ATAhmad Taha
Ahmad Taha
MOMagnus Olivecrona
Magnus Olivecrona
RBRonald Boet
Ronald Boet
TSTania Slatter
Tania Slatter
The molecular basis to overcome therapeutic resistance to treat glioblastoma remains unclear. The anti-apoptotic b cell lymphoma 2 (BCL2) gene is associated with treatment resistance, and is transactivated by the paired box transcription factor 8 (PAX8). In earlier studies, we demonstrated that increased PAX8 expression in glioma cell lines was associated with the expression of telomerase. In this current study, we more extensively explored a role for PAX8 in gliomagenesis.

1 January 2018 in EBioMedicine
Verified
Journal Article
Open access
DMDavid B Menkes
David B Menkes
PGPaul Glue
Paul Glue
CGChristopher Gale
Christopher Gale
FLFrederic Lam
Frederic Lam
CHCheung-Tak Hung
Cheung-Tak Hung
NHNoelyn Hung
Noelyn Hung
Clozapine is the most effective drug for treatment-resistant schizophrenia, but its use is limited by toxicity. Because ethnicity has been reported to affect clozapine metabolism, we compared its steady state pharmacokinetics in New Zealand Maori and European patients. Clozapine and norclozapine steady state bioavailability was assessed over 24h under fasting and fed conditions in 12 Maori and 16 European patients treated for chronic psychotic illnesses with stable once-daily clozapine doses. Plasma clozapine and norclozapine concentrations were assessed using liquid chromatography with tandem mass spectrometry; pharmacokinetic parameters were calculated using standard non-compartmental methods, and compared using unpaired t-tests. Mean pharmacokinetic parameters (AUC, Cmax and Cmin) for clozapine and norclozapine were virtually identical in Maori and European subjects, under both fed and fasted conditions. Clozapine bioavailability does not vary between Maori and European patients, and thus does not need to be considered in prescribing decisions. Additional studies are needed to identify if there are differences between Maori and European populations for drugs metabolized by other enzyme pathways.